KRAS and cancer: C3 and its active fragment C3a, downstream effectors of classical complement activation mediated by C1q/C1s/C1r, were time‐dependently increased following AZD4573 treatment, as well as PD‐L1 in KRAS‐mutant cancer cells (Figure 6D).